UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

Clinical cancer research, 2012-09, Vol.18 (17), p.4820-4829

2012

Volltextzugriff (PDF)

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

Journal of clinical oncology, 2003-05, Vol.21 (10), p.2004-2010

2003

Volltextzugriff (PDF)

In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis

European journal of nuclear medicine and molecular imaging, 2011-11, Vol.38 (11), p.2066-2076

2011

Volltextzugriff (PDF)

Positron emission tomography imaging of CD105 expression during tumor angiogenesis

European journal of nuclear medicine and molecular imaging, 2011-07, Vol.38 (7), p.1335-1343

2011

Volltextzugriff (PDF)

Swelling-activated Ca2+ channels trigger Ca2+ signals in Merkel cells

PloS one, 2008-03, Vol.3 (3), p.e1750-e1750

2008

Volltextzugriff (PDF)

Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma

Journal of clinical oncology, 2005-07, Vol.23 (19), p.4390-4398

2005

Volltextzugriff (PDF)

Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Clinical cancer research, 2007-08, Vol.13 (15), p.4448-4455

2007

Volltextzugriff (PDF)

Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA

PloS one, 2011, Vol.6 (12), p.e28005

2011

Volltextzugriff (PDF)

A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors

Investigational new drugs, 2013-06, Vol.31 (3), p.714-723

2013

Volltextzugriff (PDF)

ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW

American journal of translational research, 2012, Vol.4 (3), p.333-346

2012

Volltextzugriff (PDF)

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

Critical reviews in oncology/hematology, 2001-07, Vol.39 (1), p.181-194

2001

Volltextzugriff (PDF)

Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non–Small-Cell Lung Cancer: SWOG S9712

Journal of clinical oncology, 2006-11, Vol.24 (33), p.5242-5246

2006

Volltextzugriff (PDF)

Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105

European journal of nuclear medicine and molecular imaging, 2012, Vol.39 (1), p.138-148

2012

Volltextzugriff (PDF)

Multimodality Imaging of Breast Cancer Experimental Lung Metastasis with Bioluminescence and a Monoclonal Antibody Dual-Labeled with 89Zr and IRDye 800CW

Molecular pharmaceutics, 2012-08, Vol.9 (8), p.2339-2349

2012

Volltextzugriff (PDF)

Twice-Weekly Paclitaxel and Weekly Carboplatin With Concurrent Thoracic Radiation Followed by Carboplatin/Paclitaxel Consolidation for Stage III Non–Small-Cell Lung Cancer: A California Cancer Consortium Phase II Trial

Journal of clinical oncology, 2001-01, Vol.19 (2), p.442-447

2001

Volltextzugriff (PDF)

Radiation dosimetry results for zevalin radioimmunotherapy of rituximab‐refractory non‐hodgkin lymphoma

Cancer, 2002-02, Vol.94 (S4), p.1349-1357

2002

Volltextzugriff (PDF)

Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small-Cell Lung Cancer: Southwest Oncology Group 9713

Journal of clinical oncology, 2004-01, Vol.22 (1), p.127-132

2004

Volltextzugriff (PDF)

Choosing an optimal radioimmunotherapy dose for clinical response

Cancer, 2002-02, Vol.94 (S4), p.1275-1286

2002

Volltextzugriff (PDF)

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Blood, 2010-01, Vol.115 (3), p.489-495

2010

Volltextzugriff (PDF)

Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy

Cancer biotherapy & radiopharmaceuticals, 2003-04, Vol.18 (2), p.253-258

2003

Volltextzugriff (PDF)

Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy

International journal of radiation oncology, biology, physics, 2000-04, Vol.47 (1), p.115-119

2000

Volltextzugriff (PDF)

Antiproliferative Properties of Toremifene on AIDS-Related Kaposi’s Sarcoma Cells

Chemotherapy (Basel), 2002-12, Vol.48 (5), p.238-243

2002

Volltextzugriff (PDF)

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia

Cancer biotherapy & radiopharmaceuticals, 2003-04, Vol.18 (2), p.165-178

2003

Volltextzugriff (PDF)

Positron Emission Tomography Imaging of CD105 Expression with a .sup.64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA

PloS one, 2011-12, Vol.6 (12)

2011

Volltextzugriff (PDF)

Modulation of angiogenic biomarkers in patients receiving high-dose TRC105

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e21038-e21038

2012

Volltextzugriff (PDF)

1 – 25 von 338

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(298)
Mit Volltextzugriff
(295)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(336)
Niederländisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(200)
Life Sciences & Biomedicine
(166)
Humans
(140)
Female
(90)
Male
(79)
Biological And Medical Sciences
(52)
Middle Aged
(52)
Animals
(45)
Medical Sciences
(44)
Adult
(42)
Oncology
(41)
Aged
(38)
Endocrinology & Metabolism
(23)
Insulin Resistance
(23)
Microbiology
(18)
Aged, 80 And Over
(17)
Ecology
(17)
Environmental Sciences & Ecology
(17)
Neurosciences & Neurology
(17)
Science & Technology - Other Topics
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis

Positron emission tomography imaging of CD105 expression during tumor angiogenesis

Swelling-activated Ca2+ channels trigger Ca2+ signals in Merkel cells

Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma

Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA

A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors

ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non–Small-Cell Lung Cancer: SWOG S9712

Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105

Multimodality Imaging of Breast Cancer Experimental Lung Metastasis with Bioluminescence and a Monoclonal Antibody Dual-Labeled with 89Zr and IRDye 800CW

Twice-Weekly Paclitaxel and Weekly Carboplatin With Concurrent Thoracic Radiation Followed by Carboplatin/Paclitaxel Consolidation for Stage III Non–Small-Cell Lung Cancer: A California Cancer Consortium Phase II Trial

Radiation dosimetry results for zevalin radioimmunotherapy of rituximab‐refractory non‐hodgkin lymphoma

Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small-Cell Lung Cancer: Southwest Oncology Group 9713

Choosing an optimal radioimmunotherapy dose for clinical response

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy

Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy

Antiproliferative Properties of Toremifene on AIDS-Related Kaposi’s Sarcoma Cells

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia

Positron Emission Tomography Imaging of CD105 Expression with a .sup.64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA

Modulation of angiogenic biomarkers in patients receiving high-dose TRC105

Suchergebnisse filtern